虚增营收、隐瞒实控人资金占用，*ST苏吴重大违法陷退市风险

Group 1 - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) is facing the risk of being delisted due to significant violations, as indicated in a recent announcement [1] - The China Securities Regulatory Commission (CSRC) issued a notice confirming that the company inflated its revenue, costs, and profits, leading to false records in annual reports from 2020 to 2023 [1][2] - If the formal penalty decision confirms the violations, the company will apply for a trading suspension and disclose relevant information promptly [1] Group 2 - The company failed to accurately disclose its actual controller, with a change in control occurring in February 2018, where Qian Qunshan became the actual controller instead of Qian Qunying as reported [2] - Multiple subsidiaries of the company engaged in non-commercial trade activities with related parties, inflating revenue and profits by nearly 100 million yuan, resulting in false records in annual reports [2] - The company did not disclose significant non-operating fund occupation by related parties in its annual reports from 2020 to 2023, leading to major omissions [2]